CMED China Medical Technologies ADS, Each Representing 10 Ordinary Shares (MM)

Table of Contents

 

 

FORM 6-K

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

REPORT OF FOREIGN ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the month of November, 2010

 

 

Commission File Number: 000-51440

 

 

CHINA MEDICAL TECHNOLOGIES, INC.

(Translation of registrant’s name into English)

 

 

No. 24 Yong Chang North Road

Beijing Economic-Technological Development Area

Beijing 100176

People’s Republic of China

(Address of principal executive offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F   x             Form 40-F   ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):             

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):             

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes   ¨              No   x

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- N/A

 

 

 

---

Table of Contents

 

CHINA MEDICAL TECHNOLOGIES, INC.

Form 6-K

TABLE OF CONTENTS

 

		Page
Signature			3
Exhibit 99.1 – Press Release			4

---

Table of Contents

 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Date: November 18, 2010

---

Table of Contents

 

Exhibit 99.1

China Medical Technologies Reports Second Fiscal Quarter Financial Results

Beijing, China, November 17, 2010 - China Medical Technologies, Inc. (the “Company”) (Nasdaq: CMED), a leading China-based advanced in-vitro diagnostic (“IVD”) company, today announced its unaudited financial results for the second fiscal quarter ended September 30, 2010 (“2Q FY2010”).

2Q FY2010 Highlights

 

•

Revenues increased by 21.5% year-over-year to RMB201.8 million (US$30.2 million).

 

•

Non-GAAP net income, as defined below, increased 270.1% year-over-year to RMB65.4 million (US$9.8 million).

 

•

Non-GAAP diluted earnings per ADS*, as defined below, increased 273.1% year-over-year to RMB2.50 (US$0.37).

 

•

Adjusted EBITDA, as defined below, increased 62.6% year-over-year to RMB116.3 million (US$17.4 million).

 

•

Net cash generated from operations was RMB67.3 million (US$10.1 million).

Outlook for 3Q FY2010

 

•

Target revenues are expected to be not less than RMB220.0 million (US$32.9 million), representing a year-over-year increase of not less than 27.7%.

 

•

Target non-GAAP net income is expected to be not less than RMB74.0 million (US$11.1 million), representing a year-over-year increase of not less than 62.2%.

 

•

Target non-GAAP diluted earnings per ADS* is expected to be not less than RMB2.82 (US$0.42), representing a year-over-year increase of not less than 62.1%.

Outlook for FY2010

 

•

Target revenues are expected to be not less than RMB846.0 million (US$126.4 million), representing a year-over-year increase of not less than 17.0%. The year-over-year increase of annual revenues for FY2010 is lower than that of 3Q FY2010 because of the 10.9% year-over-year decrease in quarterly revenues of 1Q FY2010.

 

•

Target non-GAAP net income is expected to be not less than RMB280.0 million (US$41.9 million), representing a year-over-year increase of not less than 49.5%.

 

•

Target non-GAAP diluted earnings per ADS* is expected to be not less than RMB10.69 (US$1.60), representing a year-over-year increase of not less than 49.9%.

The above targets are based on the Company’s current views on the operating and market conditions, which are subject to change.

 

*	One American Depositary Share (“ADS”) = 10 ordinary shares

See “Non-GAAP Measure Disclosures” below, where the impact of certain items on reported results is discussed.

---

Table of Contents

 

“We are pleased to see the commencement of contribution from sales of HPV-DNA chips which are expected to become another main revenue stream and an important growth driver in addition to our FISH business during the next few years. We have received strong interest in our SPR equipment from many of our top tier hospital customers and significant purchase orders on our chips from hospitals which have used our chips for their patients on a regular basis. We expect substantial growth on sales of our chips in upcoming quarters. In addition, our FISH business continued its growth momentum and our ECLIA business has resumed year-over-year growth,” commented Mr. Xiaodong Wu, Chairman and Chief Executive Officer of the Company.

2Q FY2010 Unaudited Financial Results

The Company reported revenues of RMB201.8 million (US$30.2 million) for 2Q FY2010, representing a 21.5% increase from the corresponding period of FY2009.

The Company’s revenues are currently generated from two segments, molecular diagnostic systems and immunodiagnostic systems. The molecular diagnostic system segment includes FISH products and SPR products while the immunodiagnostic system segment consists of ECLIA products.

Molecular diagnostic system sales for 2Q FY2010 were RMB118.3 million (US$17.7 million), representing a 32.6% increase from the corresponding period of FY2009. The year-over-year increase was primarily due to the increase in usage of the Company’s FISH probes by existing and new hospital customers served by the Company’s direct sales personnel as well as the sales of SPR-based HPV-DNA chips of RMB3.8 million (US$0.6 million) to hospitals during 2Q FY2010.

Immunodiagnostic system sales for 2Q FY2010 were RMB83.5 million (US$12.5 million), representing an 8.7% increase from the corresponding period of FY2009. The year-over-year increase was primarily due to the increase in sales of the Company’s ECLIA reagent kits to existing and new distributors.

Gross margin was 55.2% for 2Q FY2010 which decreased year-over-year from 65.4% for the corresponding period of FY2009. Due to the commencement of sales of HPV-DNA chips, the amortization of SPR intangible assets amounted to RMB27.3 million (US$4.1 million) was classified from operating expenses to cost of revenues starting from 2Q FY2010. The year-over-year decrease in gross margin was primarily due to this change in classification. The gross margin for 2Q FY2010 would be 68.6% without this change in classification of expense.

Research and development expenses were RMB10.9 million (US$1.6 million) for 2Q FY2010, representing a 14.5% year-over-year increase. The year-over-year increase was primarily due to product research and development for FISH probes and SPR chips.

Sales and marketing expenses were RMB21.5 million (US$3.2 million) for 2Q FY2010, representing a 23.2% year-over-year increase. The year-over-year increase was primarily due to the increase in direct sales efforts for molecular diagnostic systems.

General and administrative expenses were RMB25.0 million (US$3.7 million) for 2Q FY2010, representing a 44.5% year-over-year decrease. The year-over-year decrease was primarily due to no cost of independent internal investigation and lower allowance for doubtful accounts for 2Q FY2010.

Interest expense on convertible notes was RMB32.0 million (US$4.8 million) for 2Q FY2010. As of September 30, 2010, the Company’s outstanding convertible notes of US$135 million and US$248 million bear interest at 3.5% and 4% per annum, respectively, and will mature in November 2011 and August 2013, respectively.

Interest expense on amortization of convertible notes issuance costs was RMB3.9 million (US$0.6 million) for 2Q FY2010.

---

Table of Contents

 

Interest expense on amortization of share lending costs was RMB2.5 million (US$0.4 million) for 2Q FY2010.

Income tax expense was RMB21.8 million (US$3.3 million) for 2Q FY2010. The significant income tax expense was primarily because certain expenses of the Company such as stock compensation expense, amortization of acquired intangible assets and interest expense of convertible notes were not deductible for income tax purpose. In addition, the Company was required to accrue for withholding income tax on distributable earnings generated in China during 2Q FY2010.

Net loss was RMB2.9 million (US$0.4 million) for 2Q FY2010, representing a 94.1% decrease from the corresponding period of FY2009. The significant year-over-year decrease in net loss was primarily due to growth in molecular diagnostic system sales and recovery from immunodiagnostic system sales.

Non-GAAP net income, as defined below, was RMB65.4 million (US$9.8 million) for 2Q FY2010, representing a 270.1% increase from the corresponding period of FY2009.

Earnings before interest, taxes, depreciation and amortization (“EBITDA”) was RMB107.1 million (US$16.0 million) for 2Q FY2010, representing a 66.8% increase from the corresponding period of FY2009.

Adjusted EBITDA, which excludes stock compensation expense and gain on purchase of convertible notes from EBITDA, was RMB116.3 million (US$17.4 million) for 2Q FY2010, representing a 62.6% increase from the corresponding period of FY2009.

Stock compensation expense for 2Q FY2010 was RMB9.2 million (US$1.4 million), of which RMB0.1 million was allocated to cost of revenues, RMB1.1 million to research and development expenses, RMB0.2 million to sales and marketing expenses and RMB7.8 million to general and administrative expenses. The Company approved the grant of 2,100,000 restricted stock, equivalent to 210,000 ADSs, to directors, officers and certain employees on November 5, 2010. The restricted stock vests at the end of a three-year period.

Amortization of acquired intangible assets for 2Q FY2010 was RMB49.4 million (US$7.4 million) which was all allocated to cost of revenues.

As of September 30, 2010, the Company’s cash and cash equivalents was RMB805.9 million (US$120.5 million). Net cash generated from operating activities for 2Q FY2010 was RMB67.3 million (US$10.1 million). Net cash used in investing activities for 2Q FY2010 was RMB1.2 million (US$0.2 million). There was no financing activity for 2Q FY2010.

As of September 30, 2010, the Company’s net accounts receivable was RMB333.1 million (US$49.8 million), representing an increase of 7.0% from the balance at June 30, 2010.

For the convenience of readers, certain RMB amounts have been translated into U.S. dollars at the rate of RMB6.6905 to US$1.00, the noon buying rate in New York City for cable transfers of RMB per U.S. dollar as set forth in the H.10 weekly statistical release of the Federal Reserve Board, as of Thursday, September 30, 2010. No representation is made that the RMB amounts could have been or could be converted into U.S. dollars at that rate or at any other rate on September 30, 2010 or at any other dates.

Update on Receivable from Chengxuan

The receivable of US$30 million from Chengxuan, one of the Company’s major shareholders and owned by Mr. Xiaodong Wu, is due on December 31, 2010 which relates to the sale of the Company’s HIFU business to Chengxuan. Chengxuan made an early payment of US$8 million to the Company in November 2010 and has indicated to the Company that the remaining amount will be paid on or before December 31, 2010.

---

Table of Contents

 

Non-GAAP Measure Disclosures

The Company provides gross profit, operating income, net income, earnings per ADS, EBITDA and adjusted EBITDA on a Non-GAAP basis to enable investors to better assess the Company’s operating performance. The Non-GAAP measures described by the Company are reconciled to the corresponding GAAP measures in the exhibit below titled “Reconciliations of GAAP measures to Non-GAAP measures”.

The Company reported for 2Q FY2010 and provided estimates of net income and diluted earnings per ADS for 3Q FY2010 and full year FY2010 on a Non-GAAP basis. Each of the terms used by the Company is defined as follows:

 

•

Non-GAAP gross profit represents gross profit reported in accordance with GAAP, adjusted for the effects of stock compensation expense and amortization of acquired intangible assets.

 

•

Non-GAAP operating income represents operating income reported in accordance with GAAP, adjusted for the effects of stock compensation expense and amortization of acquired intangible assets.

 

•

Non-GAAP net income represents net income reported in accordance with GAAP, adjusted for the effects of stock compensation expense, amortization of acquired intangible assets, non-cash interest expense of convertible notes, non-cash interest expense for amortization of share lending costs and gain on purchase of convertible notes.

 

•

Non-GAAP earnings per ADS represents Non-GAAP net income divided by the weighted average number of ADSs used in computing basic and diluted earnings per ADS in accordance with GAAP.

 

•

EBITDA represents net income reported in accordance with GAAP, adjusted for the effects of interest income, interest expenses, income tax expense, depreciation as well as amortization of acquired intangible assets.

 

•

Adjusted EBITDA represents EBITDA adjusted for the effects of stock compensation expense and gain on purchase of convertible notes.

Non-GAAP financial measures are used by the Company in its financial and operating decision-making because management believes they reflect the Company’s ongoing business in a manner that allows meaningful period-to-period comparison. The Company’s management believes that these non-GAAP financial measures provide useful information to investors and others in understanding and evaluating the Company’s current operating performance and future prospects in the same manner as management does, if they so choose.

The presentation of this additional financial information is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP. For a reconciliation of the non-GAAP financial measures to the most directly comparable GAAP financial measures, please see the financial information included with this earnings announcement.

Conference Call

The Company’s senior management team will host an earnings conference call at 8:00 a.m. U.S. Eastern Time on November 17, 2010 (or 9:00 p.m. Beijing/Hong Kong time on the same date) to discuss the results following this earnings announcement.

---

Table of Contents

 

The dial-in details for the live conference call are as follows:

 

•

U.S. Toll Free Number 1-800-591-6923

 

•

International Dial-in Number 1-617-614-4907

Passcode: CMEDCALL

A live webcast of the conference call will be available on http://ir.chinameditech.com .

A replay of this webcast will be available for one month on this website.

A telephone replay of the call will be available after the conclusion of the conference call through 10:00 a.m. U.S. Eastern Time on November 18, 2010.

The dial-in details for the replay are as follows:

 

•

U.S. Toll Free Number 1-888-286-8010

 

•

International Dial-in Number 1-617-801-6888

Passcode: 10798661

About China Medical Technologies, Inc.

China Medical Technologies, Inc. is a leading China-based advanced IVD company using molecular diagnostic technologies including Fluorescent in situ Hybridization (FISH) and Surface Plasmon Resonance (SPR) and an immunodiagnostic technology, Enhanced Chemiluminescence Immunoassay (ECLIA), to develop, manufacture and distribute diagnostic products used for the detection of various cancers, diseases and disorders as well as companion diagnostic tests for targeted cancer drugs. The Company generates all of its revenues in China through the sale of diagnostic consumables including FISH probes, SPR-based DNA chips and ECLIA reagent kits to hospitals which are recurring users of the consumables for their patients. The Company sells FISH probes and SPR chips to large hospitals through its direct sales force and ECLIA reagent kits to small and mid-size hospitals through distributors. For more information, please visit http://www.chinameditech.com .

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute “forward-looking” statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar statements. Among other things, the quotations from management in this press release, as well as its outlook for 3Q FY2010 and full year FY2010, contain forward-looking statements. Such statements involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Further information regarding these and other risks is included in the Company’s filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.

Contacts

Sam Tsang and Winnie Yam

Tel: 852-2511-9808

Email: IR@chinameditech.com

---

Table of Contents

 

China Medical Technologies, Inc.

Unaudited Condensed Consolidated Balance Sheets

 

		As of
		March 31, 2010				June 30, 2010				September 30, 2010
		RMB				RMB				RMB				US$
		(in thousands)
Assets
Current assets
Cash and cash equivalents			815,453				742,340				805,901				120,455
Trade accounts receivable, net			303,368				311,282				333,123				49,791
Inventories			24,889				20,177				21,351				3,191
Prepayments and other receivables			21,508				12,048				19,093				2,854
Due from a related party			204,774				203,445				200,715				30,000
Total current assets			1,369,992				1,289,292				1,380,183				206,291
Property, plant and equipment, net			155,825				151,621				147,355				22,024
Land use rights			7,049				7,001				6,954				1,039
Goodwill			8,654				8,654				8,654				1,293
Intangible assets, net			3,285,190				3,216,535				3,128,820				467,651
Convertible notes issuance costs			46,681				39,166				34,782				5,199
Share lending costs			35,678				30,744				27,905				4,171
Total assets			4,909,069				4,743,013				4,734,653				707,668
Liabilities
Current liabilities
Trade accounts payable			20,126				24,136				43,958				6,570
Accrued liabilities and other payables			183,498				186,036				173,693				25,960
Income taxes payable			57,529				56,518				59,334				8,869
Total current liabilities			261,153				266,690				276,985				41,399
Convertible notes			2,777,086				2,556,014				2,528,848				377,976
Deferred income taxes			67,134				72,518				78,408				11,720
Total liabilities			3,105,373				2,895,222				2,884,241				431,095
Shareholders’ equity
Ordinary shares US$0.1 par value: 500,000,000 authorized; 322,680,001 issued and outstanding as of March 31, 2010, June 30, 2010 and September 30, 2010			258,840				258,840				258,840				38,688
Additional paid-in capital			808,221				820,778				830,016				124,058
Treasury stock			(45,143	)			(47,108	)			(47,108	)			(7,041	)
Accumulated other comprehensive loss			(70,556	)			(70,731	)			(74,412	)			(11,122	)
Retained earnings			852,334				886,012				883,076				131,990
Total shareholders’ equity			1,803,696				1,847,791				1,850,412				276,573
Total liabilities and shareholders’ equity			4,909,069				4,743,013				4,734,653				707,668

---

Table of Contents

 

China Medical Technologies, Inc.

Unaudited Condensed Consolidated Statements of Income

 

		For the Three Months Ended
		September 30, 2009				June 30, 2010				September 30, 2010
		RMB				RMB				RMB				US$
		As adjusted (4)
		(in thousands except for per ADS information)
Revenues, net (1)			166,066				186,170				201,834				30,167
Cost of revenues (2)			(57,517	)			(61,354	)			(90,477	)			(13,523	)
Gross profit			108,549				124,816				111,357				16,644
Operating expenses
Research and development (2)			(9,500	)			(10,632	)			(10,877	)			(1,625	)
Sales and marketing (2)			(17,432	)			(18,266	)			(21,473	)			(3,209	)
General and administrative (2)			(45,130	)			(25,149	)			(25,048	)			(3,744	)
Amortization of SPR intangible assets			(27,357	)			(27,329	)			—				—
Total operating expenses			(99,419	)			(81,376	)			(57,398	)			(8,578	)
Operating income			9,130				43,440				53,959				8,066
Interest income			2,196				4,597				5,119				765
Interest expense – convertible notes			(35,439	)			(32,505	)			(32,019	)			(4,786	)
Interest expense – amortization of convertible notes issuance costs			(4,381	)			(4,012	)			(3,906	)			(584	)
Interest expense – amortization of share lending costs			(2,756	)			(2,475	)			(2,456	)			(367	)
Other (expense) income, net			(255	)			43,295				(1,802	)			(269	)
Income (loss) before income tax			(31,505	)			52,340				18,895				2,825
Income tax expense			(18,343	)			(18,662	)			(21,831	)			(3,263	)
Net income (loss)			(49,848	)			33,678				(2,936	)			(438	)
Earnings (loss) per ADS
- basic			(1.89	)			1.30				(0.11	)			(0.02	)
- diluted (3)			(1.89	)			1.29				(0.11	)			(0.02	)
Weighted average number of ADS
- basic			26,432,974				26,005,975				26,117,308				26,117,308
- diluted (3)			26,432,974				26,128,403				26,117,308				26,117,308

---

Table of Contents

 

Notes:

 

(1)	Revenues, net

 

		RMB’000				RMB’000				RMB’000				US$’000
- Molecular diagnostic systems			89,233				108,092				118,347				17,689
- Immunodiagnostic systems			76,833				78,078				83,487				12,478
			166,066				186,170				201,834				30,167
Molecular diagnostic systems
- HPV-DNA chips			—				18				3,802				568

 

(2)	Stock compensation expense

 

		RMB’000				RMB’000				RMB’000				US$’000
- Cost of revenues			—				52				117				18
- Research and development			1,256				1,418				1,145				171
- Sales and marketing			—				91				204				30
- General and administrative			6,098				9,031				7,772				1,162
			7,354				10,592				9,238				1,381

 

(3)	Interest expense and amortization in connection with convertible notes were not added back in computing diluted earnings per ADS because they were anti-dilutive.

(4)

As a result of the adoption of new authoritative guidance governing the accounting for own-share lending arrangements in contemplation of convertible debt issuance or other financing effective on April 1, 2010, the Company adjusted relevant numbers in the unaudited condensed consolidated statements of income for the three months ended September 30, 2009 retrospectively in accordance with GAAP.

---

Table of Contents

 

China Medical Technologies, Inc.

Unaudited Condensed Consolidated Statements of Cash Flows

 

		For the Three Months Ended
		September 30, 2009				June 30, 2010				September 30, 2010
		RMB				RMB				RMB				US$
		(in thousands)
Net cash provided by operating activities			45,472				69,847				67,303				10,059
Net cash used in investing activities			(357,165	)			(1,289	)			(1,244	)			(186	)
Net cash provided by (used in) financing activities			1,011				(144,537	)			—				—
Effect of foreign currency exchange rate change on cash			(155	)			2,866				(2,498	)			(372	)
Net increase (decrease) in cash and cash equivalents			(310,837	)			(73,113	)			63,561				9,501
Cash and cash equivalents:
At beginning of period			1,547,533				815,453				742,340				110,954
At end of period			1,236,696				742,340				805,901				120,455

---

Table of Contents

 

China Medical Technologies, Inc.

Reconciliations of GAAP measures to Non-GAAP measures

 

		For the Three Months Ended
		September 30, 2009				June 30, 2010				September 30, 2010
		RMB				RMB				RMB				US$
		As adjusted (2)
		(in thousands except for per ADS information)
Gross profit			108,549				124,816				111,357				16,644
Adjustments:
Stock compensation expense			—				52				117				18
Amortization of acquired intangible assets			22,430				22,414				49,422				7,386
Non-GAAP gross profit			130,979				147,282				160,896				24,048
Gross margin			65.4	%			67.0	%			55.2	%			55.2	%
Non-GAAP gross margin			78.9	%			79.1	%			79.7	%			79.7	%
Operating income			9,130				43,440				53,959				8,066
Adjustments:
Stock compensation expense			7,354				10,592				9,238				1,381
Amortization of acquired intangible assets			49,787				49,743				49,422				7,386
Non-GAAP operating income			66,271				103,775				112,619				16,833
Operating margin			5.5	%			23.3	%			26.7	%			26.7	%
Non-GAAP operating margin			39.9	%			55.7	%			55.8	%			55.8	%
Net income (loss)			(49,848	)			33,678				(2,936	)			(438	)
Adjustments:
Stock compensation expense			7,354				10,592				9,238				1,381
Amortization of acquired intangible assets			49,787				49,743				49,422				7,386
Non-cash interest expense of convertible notes			7,621				7,916				7,221				1,079
Non-cash interest expense – amortization of share lending costs			2,756				2,475				2,456				367
Gain on purchase of convertible notes			—				(47,393	)			—				—
Non-GAAP net income			17,670				57,011				65,401				9,775
GAAP net margin			—				18.1	%			—				—
Non-GAAP net margin			10.6	%			30.6	%			32.4	%			32.4	%
Net income (loss)			(49,848	)			33,678				(2,936	)			(438	)
Adjustments:
Interest income			(2,196	)			(4,597	)			(5,119	)			(765	)
Interest expense – convertible notes			35,439				32,505				32,019				4,786
Interest expense – amortization of convertible notes issuance costs			4,381				4,012				3,906				584
Interest expense – amortization of share lending costs			2,756				2,475				2,456				367
Income tax expense			18,343				18,662				21,831				3,263
Depreciation			5,521				5,475				5,497				822
Amortization of acquired intangible assets			49,787				49,743				49,422				7,386
EBITDA			64,183				141,953				107,076				16,005
EBITDA margin			38.6	%			76.2	%			53.1	%			53.1	%

---

Table of Contents

 

EBITDA			64,183				141,953				107,076				16,005
Adjustments:
Stock compensation expense			7,354				10,592				9,238				1,381
Gain on purchase of convertible notes			—				(47,393	)			—				—
Adjusted EBITDA			71,537				105,152				116,314				17,386
Adjusted EBITDA margin			43.1	%			56.5	%			57.6	%			57.6	%
Earnings (loss) per ADS
- basic			(1.89	)			1.30				(0.11	)			(0.02	)
- diluted			(1.89	)			1.29				(0.11	)			(0.02	)
Non-GAAP earnings per ADS
- basic			0.67				2.19				2.50				0.37
- diluted (1)			0.67				2.18				2.50				0.37
Weighted average number of ADS
- basic			26,432,974				26,005,975				26,117,308				26,117,308
- diluted (1)			26,432,974				26,128,403				26,117,308				26,117,308

Notes:

 

(1)	Interest expense and amortization in connection with convertible notes were not added back in computing non-GAAP diluted earnings per ADS because they were anti-dilutive.

(2)

As a result of the adoption of new authoritative guidance governing the accounting for own-share lending arrangements in contemplation of convertible debt issuance or other financing effective on April 1, 2010, the Company adjusted relevant numbers in the unaudited condensed consolidated statements of income for the three months ended September 30, 2009 retrospectively in accordance with GAAP.